Sanofi (France), Regeneron Pharmaceuticals, Inc. Drug Slashes Cholesterol in Phase 3 Trial

Sanofi and Regeneron Report Positive Top-line Results with Alirocumab from First Phase 3 Study of a PCSK9 Inhibitor for LDL Cholesterol Reduction TARRYTOWN, N.Y. /PRNewswire/ -- Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the Phase 3 ODYSSEY MONO trial with alirocumab, an investigational monoclonal antibody targeting PCSK9 , met ... (more)

http://www.biospace.com/news_story.aspx?StoryID=311902&full=1